The US Food and Drug Administration approves pitolisant (WAKIX) tablets for the treatment of cataplexy in pediatric patients aged 6 years and older with narcolepsy.
To inform about the expanded approval of pitolisant for treating narcolepsy in pediatric and adult patients.
Key Findings:
Pitolisant is the only non-scheduled therapy approved for narcolepsy in both pediatric and adult patients.
The drug was initially approved for adults in 2019 and expanded to include pediatric patients in 2024.
Common adverse reactions include insomnia, nausea, anxiety in adults, and headache, insomnia in pediatric patients.
Interpretation:
The broadened indication for pitolisant enhances treatment options for narcolepsy, addressing both excessive daytime sleepiness and cataplexy in younger patients.
Limitations:
Pitolisant is contraindicated in patients with hypersensitivity or severe hepatic impairment.
It may prolong the QT interval, posing risks for patients with cardiac issues.
Conclusion:
The FDA's approval of pitolisant for pediatric patients marks a significant advancement in the management of narcolepsy, offering new therapeutic options.
